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variability in CERs for same drugs for different indications, in some cases also varying 
by biomarkers. Primary care drugs had lower and less variable CERs than specialty 
drugs. Variations also exist in methodology used by different groups in modeling cost 
effectiveness, especially for time horizon and comparator. Majority of primary care 
drugs were modeled for a time horizon of 35–40 years or lifetime to demonstrate cost 
effectiveness. Among the top 10 drugs, quetiapine and erythropoietin had the highest 
variability across different studies, and atorvatstatin, salmetrol/ﬂuticasone and clopi-
dogrel had the most consistent ICER values across studies. CONCLUSIONS: This 
analysis shows the range, variability and methods used for calculation of ICER values 
for these high budget impact drugs and provides lessons for executives and policy 
makers.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Patient-Reported 
Outcomes Studies
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OBJECTIVES: To examine whether the move from the SF-36 to the SF-6D entails a 
loss in discriminative and evaluative strengths, the magnitude of that loss and whether 
it matters. METHODS: The study used relative validity (RV); a ratio of two F statis-
tics, and standardized response means (SRM) to evaluate sensitivity and responsive-
ness of the SF-36 scales and SF-6D index. An RV of 1 reﬂected the most sensitive/
responsive scale and the smaller the RV the less sensitive the measure would be. 
Cohen’s criterion for interpreting effect sizes was used to interpret the SRMs. The 
data used were initially collected for prior studies in seven diseases/conditions: chronic 
obstructive pulmonary disease, leg ulcers, the elderly in exercise, osteoarthritis, irri-
table bowel syndrome, migraine and obesity. Identiﬁed discriminative and evaluative 
variables were used to compare RVs and SRMs of the SF-36 scales and the SF-6D 
index. The mean RV differences and mean SRMs differences between the SF-36 scales 
and the SF-6D index represented the loss or gain in sensitivity. RESULTS: Data were 
available from a total of 10,089 subjects. No single SF-36 scale consistently had the 
largest RV or SRM, and there was no largest RV or SRM observed for the SF-6D 
index in any condition studied. Comparisons showed the SF-6D index was more 
discriminative with a mean RV difference of 0.09, (95% CI; 0.07 to 0.12) and more 
responsive with a mean SRM difference of 0.08, (95% CI; 0 to 0.16) than the SF-36 
scales. However, based on longitudinal RVs the index was less responsive with a mean 
RV difference of 0.07, (95% CI; 0.01 to 0.15) than the SF-36 scales. CONCLUSIONS: 
Moving from the SF-36 to the SF-6D index entails a loss in evaluative strength and a 
gain in discriminative strength, a loss/gain too small to matter given the merits of 
either instrument.
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OBJECTIVES: To examine patients’ preferences and satisfaction on completing 
Patient Reported Outcome (PRO) assessments in studies that compared paper-admin-
istered to electronic versions. To identify which data collection method patients prefer. 
To explore aspects that makes the PRO experience more positive or negative for 
patients. METHODS: A large literature search was conducted to gather articles that 
utilized ePRO. From that, articles were identiﬁed and reviewed that compared paper 
to ePRO and assessed for patient satisfaction/preferences. RESULTS: 119 articles were 
identiﬁed that utilized ePRO; 26 (21.8%) compared paper to ePRO. Of the 26, 17 
(65.4%) reported on patient satisfaction/preferences. Electronic modalities consisted 
of handheld devices (70.6%), interactive voice response system (IVRS) (phone) (17.6 
%), electronic data capture system (5.9%) and both IVRS and handheld (5.9%). 
Patient satisfaction/preference was assessed through either interviews (41.2%) or 
questionnaires (58.8%). Patients reported preferring ePRO over paper in 88.2% of 
the articles. Positives aspects of paper included: familiarity, not dependent on technol-
ogy that may malfunction and ease of reading. Negative aspects of paper included: 
forgetting to complete and burden. Positive aspects of ePRO included: liked the diary’s 
appearance, convenient, ease of data entry, fast/efﬁcient, saves trees, reminders, overall 
survey experience, more fun/novel, easier on eye, more up-to-date, and comfort in 
handling. Negative aspects of ePRO included: system problems/failures, difﬁculty to 
read, difﬁcult to use, instructions could have been simpler, and inability to change 
reminder time or enter data late. CONCLUSIONS: As PRO are measures that come 
directly from the patients, it is important to identify their preferences and aspects of 
what makes their experiences more positive. These ﬁndings suggest that patients 
overall preferred ePRO and identiﬁed more positive aspects for ePRO. Both positive 
and negative aspects reported are equally valuable in identifying how PRO data col-
lection can be improved to provide patients with the most positive experiences.
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OBJECTIVES: Health-related quality of life (HRQoL) instruments used in China are 
mainly from Western countries. Such instruments may not cover all the important 
health dimensions relevant to Chinese people as health is a culture-speciﬁc concept. 
However, there is a paucity of empirical data on what good health is to Chinese 
people. The objective of the current study is to identify health dimensions with which 
Chinese people use to deﬁne health. METHODS: A convenience sample of 200 adult 
Chinese (healthy persons: 80; inpatients: 120) were interviewed face to face. Open 
questions were used to elicit characteristics and life domains of good health. RESULTS: 
Fourteen health dimensions were identiﬁed. The 5 most frequently alluded dimensions 
were: mood (35.5%), absence of disease (33.3%), mobility (25.1%), ability to work 
(22.4%), and eating (17.5%). Other dimensions included vitality, pain or discomfort, 
physical ﬁtness, sleep, freedom, self-care, social relationship, enjoyment, and cogni-
tion. More proportion of healthy persons than patients quoted mood and self-care as 
dimensions of health while more patients emphasized ability to work. Males regarded 
eating as a health dimension more often than females while females quoted self-care 
and social relationship more frequently than males. With regard to age, older persons 
valued ability to work more than younger people while more younger people thought 
absence of pain or discomfort is a characteristic of good health. CONCLUSIONS: 
This study provides useful information for assessing the adequacy of HRQoL instru-
ments developed in Western countries for the Chinese population in China.
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OBJECTIVES: The EQ-5D has been translated into many languages. The Euroqol 
group have recently altered and clariﬁed the VAS scale. The objective of this study 
was to produce translations that are conceptually equivalent to the original and to 
other language versions, ensuring the relevance of the translations within the target 
cultures. METHODS: A standard methodology was employed: 1 forward and 1 back 
translation, review and developer review; or an in-country review and developer 
review; linguistic validation interviews with 8 subjects, a mix of healthy people and 
patients, a second developer review and 2 proofreadings. RESULTS: The translation 
process highlighted numerous cultural and linguistic issues, including: 1) Cognitive 
interviews showed that there was no clear Dutch word for scale, so an explanation 
likening the scale to a thermometer as in the previous 3L VAS was necessary; 2) In 
some cultures ‘mark an X on the scale’ was difﬁcult to render, and had to be amended 
by using alternative verb formations and formatting; 3) Though the new VAS mentions 
only ‘health’, in some languages, it was necessary to use “health state” to avoid confu-
sion, e.g. in Czech “health” alone means “good health.”; 4) In some languages the 
concepts of “health” and “health state” had different temporal associations. In 
Korean, “health” referred to a longer period of time, so “health today” had to be 
expressed by “health state today”; 5) Russian patients understood “health state” as 
the evaluation given by a doctor or test results, therefore “in your opinion” was added. 
CONCLUSIONS: The EQ-5D VAS has been translated and linguistically validated 
using a rigorous translation process. A number of cultural and linguistic issues became 
apparent and were resolved. The measure is now appropriate for use in multinational 
trials.
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OBJECTIVES: Patient-reported outcomes (PRO) have received increasing attention 
from regulatory agencies regarding intended use of the data for promotional labeling 
claims. However, some disease areas and/or regulatory bodies necessitate the use of 
PRO data to substantiate product efﬁcacy for securing approval. Therefore, the 
research objective was to determine how many of the ﬁnal product development guid-
ance available from EMEA and FDA for clinical/medical research indicate PRO as a 
mandatory component of efﬁcacy. METHODS: Final guidance documents from the 
EMEA and FDA were reviewed for mention of PRO. EMEA Guidance documents 
that fell under the following categories were excluded: Clinical Pharmacology and 
Pharmacokinetics, Blood and Blood Forming Organs, Blood products (including 
biotech alternatives), and Herbals. Included in FDA Guidance review were those listed 
under the “Clinical/Medical” heading. The following data were abstracted from each 
guidance: guidance number, name, issue date, disease area, body system classiﬁcation, 
PRO requirement, PRO endpoint hierarchy, and a summary of the PRO language 
included in the guidance. PRO statements were then characterized within each of the 
following categories (yes/no): signs/symptoms, function/feeling, HRQOL, or patient 
global rating. RESULTS: Of the 134 ﬁnal guidance documents reviewed (EMEA = 81, 
FDA = 53), 52 mention PRO (EMEA n = 39; FDA n = 13). Within EMEA, PRO is 
